The Panel

Claus Andersen, partner in the Life Sciences group at Freeths law firm in Oxford. Claus specialises in corporate and commercial work with a focus on mergers and acquisitions of companies and businesses in the life sciences and technology sector.

Philip Campbell is Commercial Director at Milton Park near Abingdon, the largest single ownership science community in the UK.

Keith Errey is founder and CEO of Isansys which has developed an advanced patient monitoring system: the Patient Status Engine. The software produces high resolution and dynamic digital images of patients to support clinical decision making.

Graham Griffiths is Chief Business Officer at Vaccitech plc, a spin-out from the University of Oxford. The company’s proprietary platform includes Chimpanzee Adenovirus Oxford (ChAdOx), which formed the basis of the Oxford AstraZeneca Covid 19 vaccine.

Simon Jones is Vice-President of Finance and Operations at SpyBiotech, a University of Oxford spin-out biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases.

Michalis Papadakis, is co-founder and CEO of Brainomix Ltd. Another spin-out from the University of Oxford, Brainomix’s AI imaging platform includes e-Stroke, a comprehensive stroke imaging solution which has been adopted across multiple healthcare systems worldwide.

Miguel Silva is Strategy Director at OMass Therapeutics, a biotechnology company spun out of the University of Oxford discovering medicines against highly-validated target ecosystems. The company uses novel biochemistry techniques, next generation native mass spectrometry and custom chemistry to interrogate how a target interacts with its native ecosystem.

Adam Stoten is Site Head for Evotec’s Dorothy Crowfoot Hodgkin Campus in Abingdon. Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to patients. Evotec employs more than 4,500 people worldwide, including around 800 at Milton Park.

Deborah Spencer is the Oxford University Lead for the UK Industrial Strategy based within the Mathematical, Physical and Life Sciences Division. She works at the interface of industry and academia in innovation and strategic business partnerships. She leads on a quantum computing and drug discovery programme for the University and recently founded the Oxford Water Quality Centre.

Ben Thomas is Senior Director External Innovation and Operations at Oxford BioTherapeutics, a clinical stage oncology company focused only on first-in-class immune therapies. Its lead asset is an Antibody Drug Conjugate in Phase 1b clinical development.